HIGHLIGHTS
- who: Zoya Peelay and colleagues from the Department of Medical Oncology, Tata Memorial Hospital, HBNI, Parel, Mumbai, India have published the paper: Real-world analysis of the use of lenvatinib in differentiated thyroid cancers, in the Journal: (JOURNAL)
- what: The aim was to study the efficacy of lenvatinib and the secondary objective was to study the adverse events and compliance in dedifferentiated thyroid cancers. N=27 Response rate Stable disease (SD) Progressive disease (PD) Research Response - No(%) Compared to the SELECT trial , which also studied the efficacy of Lenvatinib, the study reported a slightly lower . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.